| Dr Marco Diaz, MD | |
|
6283 Franklin Point Dr, El Paso, TX 79912-8180 | |
| (915) 929-1069 | |
| Not Available |
| Full Name | Dr Marco Diaz |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 18 Years |
| Location | 6283 Franklin Point Dr, El Paso, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104015577 | NPI | - | NPPES |
| 205287005 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | N0730 (Texas) | Secondary |
| 207P00000X | Emergency Medicine | N0730 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Las Palmas Medical Center | El paso, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Fmuc Pllc | 6103191978 | 2 |
News Archive
Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Rotigotine Extended-release Transdermal Film, 1 mg/24 hr, 2mg/24 hr, 3 mg/24hr, 4 mg/24 hr, 6mg/24hr, and 8 mg/24 hr.
Specializing in one sport early in a child's athletic career is often touted as a way to gain that elusive college scholarship or even go on to the pros.
MAP Pharmaceuticals, Inc. today announced that the Company will present new analyses from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX™ orally inhaled migraine therapy. The post hoc analyses will be presented at the 52nd Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, California.
Five Dartmouth College alumni and health care investors have committed a total of $1.4 million in gifts to launch the Dartmouth Innovations Accelerator for Cancer.
› Verified 5 days ago
| Entity Name | Questcare Medical Services Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164574489 PECOS PAC ID: 6204739402 Enrollment ID: O20040127000697 |
News Archive
Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Rotigotine Extended-release Transdermal Film, 1 mg/24 hr, 2mg/24 hr, 3 mg/24hr, 4 mg/24 hr, 6mg/24hr, and 8 mg/24 hr.
Specializing in one sport early in a child's athletic career is often touted as a way to gain that elusive college scholarship or even go on to the pros.
MAP Pharmaceuticals, Inc. today announced that the Company will present new analyses from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX™ orally inhaled migraine therapy. The post hoc analyses will be presented at the 52nd Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, California.
Five Dartmouth College alumni and health care investors have committed a total of $1.4 million in gifts to launch the Dartmouth Innovations Accelerator for Cancer.
› Verified 5 days ago
| Entity Name | Nuch Of Texas |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760722334 PECOS PAC ID: 4880833698 Enrollment ID: O20130626000489 |
News Archive
Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Rotigotine Extended-release Transdermal Film, 1 mg/24 hr, 2mg/24 hr, 3 mg/24hr, 4 mg/24 hr, 6mg/24hr, and 8 mg/24 hr.
Specializing in one sport early in a child's athletic career is often touted as a way to gain that elusive college scholarship or even go on to the pros.
MAP Pharmaceuticals, Inc. today announced that the Company will present new analyses from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX™ orally inhaled migraine therapy. The post hoc analyses will be presented at the 52nd Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, California.
Five Dartmouth College alumni and health care investors have committed a total of $1.4 million in gifts to launch the Dartmouth Innovations Accelerator for Cancer.
› Verified 5 days ago
| Entity Name | Emergency Services Of Texas Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174932131 PECOS PAC ID: 7517289291 Enrollment ID: O20141208002099 |
News Archive
Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Rotigotine Extended-release Transdermal Film, 1 mg/24 hr, 2mg/24 hr, 3 mg/24hr, 4 mg/24 hr, 6mg/24hr, and 8 mg/24 hr.
Specializing in one sport early in a child's athletic career is often touted as a way to gain that elusive college scholarship or even go on to the pros.
MAP Pharmaceuticals, Inc. today announced that the Company will present new analyses from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX™ orally inhaled migraine therapy. The post hoc analyses will be presented at the 52nd Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, California.
Five Dartmouth College alumni and health care investors have committed a total of $1.4 million in gifts to launch the Dartmouth Innovations Accelerator for Cancer.
› Verified 5 days ago
| Entity Name | Fmuc Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225568330 PECOS PAC ID: 6103191978 Enrollment ID: O20171004000976 |
News Archive
Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Rotigotine Extended-release Transdermal Film, 1 mg/24 hr, 2mg/24 hr, 3 mg/24hr, 4 mg/24 hr, 6mg/24hr, and 8 mg/24 hr.
Specializing in one sport early in a child's athletic career is often touted as a way to gain that elusive college scholarship or even go on to the pros.
MAP Pharmaceuticals, Inc. today announced that the Company will present new analyses from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX™ orally inhaled migraine therapy. The post hoc analyses will be presented at the 52nd Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, California.
Five Dartmouth College alumni and health care investors have committed a total of $1.4 million in gifts to launch the Dartmouth Innovations Accelerator for Cancer.
› Verified 5 days ago
| Entity Name | Pearsall Emergency Medicine Associates, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104326263 PECOS PAC ID: 1557623147 Enrollment ID: O20180319002335 |
News Archive
Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Rotigotine Extended-release Transdermal Film, 1 mg/24 hr, 2mg/24 hr, 3 mg/24hr, 4 mg/24 hr, 6mg/24hr, and 8 mg/24 hr.
Specializing in one sport early in a child's athletic career is often touted as a way to gain that elusive college scholarship or even go on to the pros.
MAP Pharmaceuticals, Inc. today announced that the Company will present new analyses from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX™ orally inhaled migraine therapy. The post hoc analyses will be presented at the 52nd Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, California.
Five Dartmouth College alumni and health care investors have committed a total of $1.4 million in gifts to launch the Dartmouth Innovations Accelerator for Cancer.
› Verified 5 days ago
| Entity Name | Hospitalist Medicine Physicians Of Texas - Houston, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760028740 PECOS PAC ID: 2860881125 Enrollment ID: O20211109000125 |
News Archive
Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Rotigotine Extended-release Transdermal Film, 1 mg/24 hr, 2mg/24 hr, 3 mg/24hr, 4 mg/24 hr, 6mg/24hr, and 8 mg/24 hr.
Specializing in one sport early in a child's athletic career is often touted as a way to gain that elusive college scholarship or even go on to the pros.
MAP Pharmaceuticals, Inc. today announced that the Company will present new analyses from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX™ orally inhaled migraine therapy. The post hoc analyses will be presented at the 52nd Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, California.
Five Dartmouth College alumni and health care investors have committed a total of $1.4 million in gifts to launch the Dartmouth Innovations Accelerator for Cancer.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Marco Diaz, MD 6283 Franklin Point Dr, El Paso, TX 79912-8180 Ph: (915) 929-1069 | Dr Marco Diaz, MD 6283 Franklin Point Dr, El Paso, TX 79912-8180 Ph: (915) 929-1069 |
News Archive
Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Rotigotine Extended-release Transdermal Film, 1 mg/24 hr, 2mg/24 hr, 3 mg/24hr, 4 mg/24 hr, 6mg/24hr, and 8 mg/24 hr.
Specializing in one sport early in a child's athletic career is often touted as a way to gain that elusive college scholarship or even go on to the pros.
MAP Pharmaceuticals, Inc. today announced that the Company will present new analyses from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX™ orally inhaled migraine therapy. The post hoc analyses will be presented at the 52nd Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, California.
Five Dartmouth College alumni and health care investors have committed a total of $1.4 million in gifts to launch the Dartmouth Innovations Accelerator for Cancer.
› Verified 5 days ago
Shanna Michelle Calero, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2001 N Oregon St, El Paso, TX 79902 Phone: 915-577-6011 | |
Ricardo Parra, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 4800 Alberta Ave, El Paso, TX 79905 Phone: 915-215-8000 | |
Dr. Sirous N Partovi, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 10301 Gateway Blvd W, El Paso, TX 79925 Phone: 915-595-9000 | |
Marie Percy, M.D. Emergency Medicine Medicare: May Accept Medicare Assignments Practice Location: 2200 N Lee Trevino Dr Ste A3, El Paso, TX 79936 Phone: 915-594-2772 Fax: 915-594-2774 | |
Nicholas Reiter, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 4800 Alberta Ave, El Paso, TX 79905 Phone: 915-215-8000 | |
Dr. Steven Lee Ellis, D.O. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 4801 Alberta Ave, El Paso, TX 79905 Phone: 915-545-7333 | |
Albert De La Garza, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 5005 N Piedras St, William Beaumont Army Medical Center, El Paso, TX 79920 Phone: 915-569-1386 Fax: 915-569-1233 |